trial · primary record
PD1+ TILs (NUMARZU-001) product infusion
Metastatic Triple-Negative Breast Carcinoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 20 |
| Primary completion | 2032-03-30 |
| Primary endpoint | Incidence of grade 3-5 adverse event (AE) |
| Registry ID | NCT05451784 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:15.065Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05451784
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.